Overview

A Drug Interaction Study of Boceprevir in Combination With Amlodipine or Diltiazem in Healthy Volunteers

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetic interactions between the hepatitis C NS3 protease inhibitor boceprevir and the calcium channel blockers amlodipine and diltiazem in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Ottawa Hospital Research Institute
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Amlodipine
Calcium Channel Blockers
Diltiazem